Table 2 Cox regression overall survival analysis.

From: The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

 

Univariate analysis

Multivariate analysis

HR

95% CI

p value

HR

95% CI

p value

ECOG

0.96

0.59–1.56

0.869

1.16

0.67–2.00

0.548

Age > 65

0.81

0.50–1.31

0.394

0.79

0.47–1.33

0.376

Smoking history

0.72

0.42–1.48

0.463

0.80

0.35–1.79

0.580

Gender

1.81

1.10–2.98

0.019

1.76

0.91–3.40

0.090

Brain metastasis

1.14

0.69–1.87

0.620

1.22

0.72–2.06

0.463

Liver metastasis

0.96

0.52–1.75

0.882

1.08

0.58–2.03

0.805

Anti-angiogenesis

0.51

0.29–0.88

0.016

0.50

0.27–0.91

0.025

T790M

0.98

0.58–1.64

0.932

1.19

0.68–2.08

0.548

Back to article page